Jesse A. Berlin
Johnson & Johnson Pharmaceutical Research and Development
37 Papers
4.8K Citations
Jesse A. Berlin is an academic researcher from Johnson & Johnson Pharmaceutical Research and Development. The author has contributed to research in topics: Medicine & Odds ratio. The author has an hindex of 21, co-authored 37 publications. Previous affiliations of Jesse A. Berlin include Hospital of the University of Pennsylvania & University of Medicine and Dentistry of New Jersey.
Chat about Author
Papers
When pharmaceutical manufacturers' employees present grand rounds, what do residents remember?
TL;DR: The results suggest that grand rounds effectively change residents' beliefs, but a sponsoring company's drug may be favored.
Comparison of methods for correcting population stratification in a genome-wide association study of rheumatoid arthritis: principal-component analysis versus multidimensional scaling
TL;DR: While both methods identified similar population structures in this dataset, principal-component analysis performed slightly better than the multidimensional-scaling method in correcting for PS in genome-wide association analysis of this dataset.
Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team
Brenda J. Crowe,H. Amy Xia,Jesse A. Berlin,Douglas J. Watson,Hongliang Shi,Stephen L Lin,Juergen Kuebler,Robert C Schriver,Nancy C. Santanello,George Rochester,Jane B Porter,Manfred Oster,Devan V. Mehrotra,Zhengqing Li,Eileen C King,Ernest S Harpur,David B. Hall +16 more
TL;DR: A proactive approach to safety planning has the potential to benefit patients and health care providers by providing more comprehensive safety information at the time of new product marketing and beyond.
Risk factors for early postoperative recurrence of Crohn's disease ☆
TL;DR: A perforating indication for initial resection and a longer duration of disease before initial surgery predicted an earlier postoperative recurrence, which suggests that prognostic groups based on these factors may help to stratify patients with regard to risk of early recurrence.
Insulin Sensitizing Pharmacotherapy for Prevention of Myocardial Infarction in Patients With Diabetes Mellitus
TL;DR: The use of insulin-sensitizing drugs is associated with a significantly reduced risk of MI compared with sulfonylurea use, and the addition of a thiazolidinedione to sulfonyLurea monotherapy isassociated with a lower risk ofMI.